Trajectories of CD4<sup>+</sup>/CD8<sup>+</sup> T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study
Lucia Taramasso,
Antonio Falletta,
Elena Ricci,
Giancarlo Orofino,
Nicola Squillace,
Barbara Menzaghi,
Giuseppe Vittorio De Socio,
Chiara Molteni,
Giovanni Francesco Pellicanò,
Roberto Gulminetti,
Giordano Madeddu,
Eleonora Sarchi,
Francesca Vichi,
Benedetto Maurizio Celesia,
Paolo Bonfanti,
Antonio Di Biagio
Affiliations
Lucia Taramasso
Infectious Diseases Unit, San Martino Policlinico Hospital, IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy
Antonio Falletta
Department of Health Sciences (DiSSal), University of Genova, 16132 Genova, Italy
Elena Ricci
Fondazione A.S.I.A. Onlus, 20100 Milan, Italy
Giancarlo Orofino
Division I of Infectious and Tropical Diseases, ASL Città di Torino, 10149 Turin, Italy
Nicola Squillace
Infectious Diseases Unit ASST-MONZA, San Gerardo Hospital, University of Milano-Bicocca, 20900 Monza, Italy
Barbara Menzaghi
Unit of Infectious Diseases, ASST della Valle Olona, 21052 Busto Arsizio, Italy
Giuseppe Vittorio De Socio
Infectious Diseases Unit, Department of Internal Medicine 2, “Santa Maria della Misericordia” General Hospital, 06129 Perugia, Italy
Chiara Molteni
Infectious Diseases Unit, Ospedale A. Manzoni, 23900 Lecco, Italy
Giovanni Francesco Pellicanò
Unit of Infectious Diseases, Department of Human Pathology of the Adult and the Developmental Age “G. Barresi”, University of Messina, 98124 Messina, Italy
Roberto Gulminetti
Department of Medical Sciences and Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
Giordano Madeddu
Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy
Eleonora Sarchi
Infectious Diseases Unit, S. Antonio e Biagio e Cesare Arrigo Hospital, 15121 Alessandria, Italy
Francesca Vichi
Infectious Diseases Unit, Santa Maria Annunziata Hospital, 50012 Bagno a Ripoli, Italy
Benedetto Maurizio Celesia
Unit of Infectious Diseases, University of Catania, ARNAS Garibaldi Catania, 95123 Catania, Italy
Paolo Bonfanti
Infectious Diseases Unit ASST-MONZA, San Gerardo Hospital, University of Milano-Bicocca, 20900 Monza, Italy
Antonio Di Biagio
Infectious Diseases Unit, San Martino Policlinico Hospital, IRCCS for Oncology and Neurosciences, 16132 Genoa, Italy
The aim of the present study was to evaluate CD4/CD8 dynamics in patients on dolutegravir (DTG)-based two-drug regimens (2DRs) and compare them with DTG-containing triple-drug regimens (3DRs). A prospective observational study was performed in the context of the SCOLTA cohort. Experienced PWH with HIV-RNA < 50 copies/mL were included if they were on the DTG-2DR, the DTG + tenofovir/emtricitabine (TDF/FTC) regimen, the DTG + tenofovir alafenamide (TAF)/FTC regimen, or the DTG + abacavir/lamivudine (ABC/3TC) regimen; they were followed-up for at least one year. A total of 533 PWH were enrolled, 120 in the DTG + 3TC group, 38 in the DTG + protease inhibitors (PI) group, 67 in the DTG + rilpivirine (RPV) group, 49 in the DTG + TDF/FTC group, 27 in the DTG + TAF/FTC group, and 232 in the DTG + ABC/3TC group. After one year, the CD4/CD8 ratio significantly increased in the PWH treated with DTG + 3TC (+0.08 ± 0.26), DTG + TDF/FTC (+0.1 ± 0.19), and DTG + ABC/3TC (+0.08 ± 0.25). At two years, the CD4/CD8 increase was confirmed for PWH on DTG + TDF/FTC (+0.16 ± 0.28) and DTG + ABC/3TC (+0.1 ± 0.3). In the SCOLTA cohort, PWH on 2DRs experienced a CD4/CD8 increase only in the DTG + 3TC group. Controlled studies with longer follow-up will clarify the long-term immunological and clinical impacts of DTG-2DR.
